Hematology and Oncology Fellowship: Presbyterian Hospital in the City of New York Columbia University College of Physicians and Surgeons
Internal Medicine: Alton Ochsner Medical Foundation, July 1981-June 1984
MD: LSU School of Medicine, 1981
Assistant Professor of Clinical Medicine
Staff Member, Section of Hematology/Oncology
|Committees & Administrative Responsibilities||
Acting Section Chief- Hematology/Oncology, LSUHSC, 2008-2014
Claudia P. Hernandez, Kevin Morrow, Lluis A. Lopez-Barcons, Jovanny Zabaleta, Rosa Sierra, Cruz Velasco, John Cole, and Paulo C. Rodriguez. Pegylated arginase I: a potential therapeutic approach in T-ALL Blood, Jun 2010; 115: 5214 - 5221.
Lee, C., Das, B., Lin, T., Grimes, C., Zhang, X., Lavezzi, T., Huang, L., Cole, J., Yau, L., Li, L. A rare fraction of drug-resistant follicular lymphoma cancer stem cells interacts with follicular dendritic cells to maintain tumourigenic potential. British Journal of Hematology, 2012, 158, 79-90.
Perez EA, Suman VJ, Fitch TR, Mailliard JA, Ingle JN, Cole JT, Veeder MH, Flynn PJ, Walsh DJ, Addo FK: A Phase II Trial of Docetaxel and Carboplatin as First-Line Chemotherapy for Metastatic Breast Cancer: NCCTG Study N9932. Oncology 2005; 69:117-121.
Cole JT, McElroy EA, Marques CB, Castillo RA, Gralla RJ: Phase I study of weekly paclitaxel and vinorelbine in patients with advanced solid tumors. Proceedings of American Society of Clinical Oncology 22:606-150, 2003.
Gonzales-Angulo AM, Suarez J, Fuloria J, Cole JT, Kardinal CG: Prognostic implications of immunohistochemical detection in sentinel lymph nodes of breast cancer patients. Proceedings of American Society of Clinical Oncology 21:3568-887, 2003.
“Locally Advanced Breast Cancer” John T. Cole in Cancer of the Breast, 5th Edition, Donegan WL and Spratt JS, Ed. W.B. Sanders. pg 579 – 595, 2002.
Natale RB, Skarin A, Maddox AM, Hammond LA, Thomas R, Gandara DR, Gerstein H, Panella T, Cole J, Jahanzeb M, Kash J, Hamm J, Langer C, Saleh M, Stella P, Heyes A, Helms L, Ochs J, Averbuch S, Wolf M, Kay A: Improvement in symptoms and quality of life for advanced non-small cell lung cancer patients receiving ZD1839 (“Iressa”) in IDEAL 2. Proceeding of American Society of Clincal Oncology 21:1167-292A, 2002.
Buckner JC, Schomberg PJ, McGinnis WL, Cascino TL, Scheithauer BW, O’Fallon J, Morton RF, Kuross SA, Mailliard JA, Hatfield AK, Cole JT, Steen PD, Bernath AM: A Phase III Study of Radiation Therapy plus Carmustine with or without Recombinant Interferon-α in the Treatment of Patients with Newly Diagnosed High-Grade Glioma. Cancer 92:420-33, 2001.
Kardinal CG, Cole JT; Breast Cancer (in) The Chemotherapy Source Book. 5th edition. JW Pine, Editor, Chapter 32, 401-444. Lippincott, Williams, Wilkins. 2012.